Opinion

Video

Safety and Efficacy of Janus Kinase Inhibitors

Panelists discuss how the findings from the ORAL Surveillance study regarding cardiovascular and cancer risks associated with tofacitinib have influenced perceptions of JAK inhibitors, emphasizing the need to balance safety concerns with their efficacy in managing rheumatoid arthritis.

Video content above is prompted by the following:

Results from the 2021 ORAL Surveillance study showed the Janus kinase inhibitor (JAKi) tofacitinib was associated with a cardiovascular and cancer risk.

  • Can you describe concerns and misperceptions that ensued from results of the ORAL Surveillance study? What were the limitations of the study?
  • Can you please share how you weigh JAKi safety concerns with their efficacy outcomes?
  • In your clinical observations, what role have JAKis played in helping patients with rheumatoid arthritis achieve remission?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
Safety Profile, Accessibility of Tapinarof Cream for Atopic Dermatitis, with Adelaide Hebert, MD
Impact of Tapinarof Cream Approval for Atopic Dermatitis, with Adelaide Hebert, MD
Sobia Laique, MD | Credit: Cleveland Clinic
Sobia Laique, MD | Credit: Cleveland Clinic
What is the Global Lung Function Initiative and Its Purpose for Lung Function Testing?
© 2025 MJH Life Sciences

All rights reserved.